Iovance Biotherapeutics (NASDAQ:IOVA) Upgraded at Zacks Research

Posted by George Bondi on Oct 28th, 2026

Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Monday, Zacks reports.

Other equities research analysts also recently issued reports about the stock. The Goldman Sachs Group assumed coverage on shares of Iovance Biotherapeutics in a research note on Thursday, September 24th. They set a “buy” rating and a $15.00 price target for the company. Citigroup reaffirmed an “outperform” rating on shares of Iovance Biotherapeutics in a research note on Friday, August 7th. TD Cowen raised their price objective on shares of Iovance Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Monday, August 24th. Barclays lifted their target price on shares of Iovance Biotherapeutics from $15.00 to $18.00 and gave the stock an “overweight” rating in a report on Tuesday, October 13th. Finally, Robert W. Baird upped their target price on shares of Iovance Biotherapeutics from $6.00 to $11.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Iovance Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $13.20.

Check Out Our Latest Research Report on Iovance Biotherapeutics

Iovance Biotherapeutics Price Performance

Shares of NASDAQ:IOVA opened at $14.58 on Monday. Iovance Biotherapeutics has a 1-year low of $1.76 and a 1-year high of $15.37. The business has a 50-day moving average price of $11.19 and a two-hundred day moving average price of $5.70.

Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last released its earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The business had revenue of $99.31 million for the quarter, compared to analyst estimates of $87.83 million. The business’s revenue for the quarter was up 65.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.33) earnings per share. On average, equities research analysts anticipate that Iovance Biotherapeutics will post -0.45 earnings per share for the current year.

Institutional Trading of Iovance Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. KBC Group NV acquired a new stake in shares of Iovance Biotherapeutics in the 1st quarter valued at approximately $34,000. Sanctuary Advisors LLC bought a new position in Iovance Biotherapeutics during the 1st quarter worth approximately $38,000. Valley National Advisers Inc. acquired a new position in Iovance Biotherapeutics during the third quarter valued at approximately $38,000. Fifth Third Bancorp acquired a new position in Iovance Biotherapeutics during the first quarter valued at approximately $39,000. Finally, Ceera Investments LLC acquired a new position in Iovance Biotherapeutics during the first quarter valued at approximately $44,000. 77.03% of the stock is owned by institutional investors.

Iovance Biotherapeutics Company Profile

(Get Free Report)

Iovance Biotherapeutics, Inc (NASDAQ: IOVA) is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.